- Home
- DQ vs DAWN Comparison
DQ vs DAWN Comparison
Compare DQ & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- DAWN
- Stock Information
- Founded
- DQ 2006
- DAWN 2018
- Country
- DQ China
- DAWN United States
- Employees
- DQ N/A
- DAWN N/A
- Industry
- DQ Semiconductors
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- DAWN Health Care
- Exchange
- DQ Nasdaq
- DAWN Nasdaq
- Market Cap
- DQ 1.4B
- DAWN 1.2B
- IPO Year
- DQ 2010
- DAWN 2021
- Fundamental
- Price
- DQ $18.49
- DAWN $8.07
- Analyst Decision
- DQ Hold
- DAWN Strong Buy
- Analyst Count
- DQ 5
- DAWN 7
- Target Price
- DQ $20.31
- DAWN $32.29
- AVG Volume (30 Days)
- DQ 837.3K
- DAWN 1.3M
- Earning Date
- DQ 04-28-2025
- DAWN 05-05-2025
- Dividend Yield
- DQ N/A
- DAWN N/A
- EPS Growth
- DQ N/A
- DAWN N/A
- EPS
- DQ N/A
- DAWN N/A
- Revenue
- DQ $1,029,080,000.00
- DAWN $131,161,000.00
- Revenue This Year
- DQ N/A
- DAWN $28.72
- Revenue Next Year
- DQ $68.28
- DAWN $73.78
- P/E Ratio
- DQ N/A
- DAWN N/A
- Revenue Growth
- DQ N/A
- DAWN N/A
- 52 Week Low
- DQ $13.62
- DAWN $7.88
- 52 Week High
- DQ $30.85
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- DQ 44.46
- DAWN 36.05
- Support Level
- DQ $17.93
- DAWN $7.93
- Resistance Level
- DQ $21.15
- DAWN $8.44
- Average True Range (ATR)
- DQ 0.93
- DAWN 0.44
- MACD
- DQ -0.10
- DAWN 0.09
- Stochastic Oscillator
- DQ 20.60
- DAWN 17.59
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.